June 21 (UPI) --The National Institutes of Health office responsible for issuing federal guidelines related to treatment of HIV and AIDS patients in the United States plans to phase them out next year ...
The Trump administration's funding cuts to PEPFAR and USAID disrupted global HIV treatment and prevention, threatening progress made over decades. Lenacapavir's FDA approval as a long-acting ...
The National Institutes of Health’s support for federal guidelines that steer the treatment of more than a million HIV patients in the United States will be phased out by next June, according to the ...
See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. The future may be getting brighter in terms of reducing the threat of ...
A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year. Gilead Sciences, GSK, ViiV Healthcare 1 to 3 years In June 2024, results from a trial ...
Mike Hellman has been managing HIV for years with aid from a special pharmaceutical benefit program funded by the state and federal government. When Mike Hellman was first diagnosed with HIV at 27, he ...
In 1981, physicians in Los Angeles reported five young patients with Pneumocystis pneumonia, a rare lung infection later recognized as the first sign of HIV infection and a defining illness of AIDS.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results